A multinational study led by Principal Investigator A/Prof. David Tan and collaborators from Singapore and South Korea has demonstrated encouraging results for patients with recurrent clear cell ovarian and endometrial cancers—rare and aggressive subtypes that often respond poorly to standard treatments.
Published in The Lancet Oncology, the Phase 2 LARA trial found that combining immunotherapy (pembrolizumab) with targeted therapy (lenvatinib) achieved a 40% tumour response rate, with manageable side effects. This dual-pathway approach enhances the immune system’s ability to attack cancer cells while disrupting tumour growth signals.